The incidence of Candida bloodstream infection (BSI) has increased during the past decades. Species distribution is changing worldwide, and non-albicans Candida spp. are becoming more prevalent. Acquired resistance to antifungal agents has been documented in several reports. The aim of our study was to assess the epidemiology and antifungal susceptibility of Candida isolates from BSI at our institute. The incidence of Candida BSI increased during the fi rst four years of our investigation, from 1.7 to 3.5 episodes / 10 000 admissions, then dropped to 2.66 episodes / 10 000 admissions in the last year. The most frequently isolated species was C. albicans (63%), followed by C. glabrata (13%), C. parapsilosis (10.2%), C. tropicalis (9.3%), and C. krusei (3.7%). One isolate each of C. kefyr, C. fabianii and C. inconspicua were detected. The percentage of C. albicans remained stable throughout the study period. The most frequent risk factors of Candida BSI in our patient population were intensive care treatment (60.4%), abdominal surgery (52.5%), and solid malignancy (30.7%). All isolates were wild-type organisms, no acquired antifungal resistance was detected.
Introduction
Candida spp. are a leading cause of bloodstream infection (BSI), associated with high mortality and increased hospital costs [1] . The annual incidence of Candida BSI varies greatly by region based on epidemiological studies from Blood samples were collected and processed using either the Bactec™ 9120 (Beckton Dickinson) or BacT/ALERT ® 3D (BioMérieux) automated blood culture systems. Isolates were identifi ed by phenotypic methods [carbohydrate assimilation profi le obtained by the API 20C AUX system (BioMérieux), and morphology of pseudohyphae on malt agar] and matrix-assisted laser desorption/ ionization time-of-fl ight mass spectrometry (MALDI-TOF/MS, Bruker) analysis. Routine antifungal susceptibility testing was performed by E-test ® (BioMérieux) method, according to the manufacturer's instructions. Minimal inhibitory concentration (MIC) results were interpreted according to EUCAST clinical breakpoints [19] .
Fisher's exact test was used to assess if any of the risk factors of candidaemia had any connection with 30-day mortality and to describe changes in isolate incidence. A p value of <0.05 was considered signifi cant.
Results

Incidence
Candidaemia was detected in 129 cases in adult patients between 2010-2014. The number of episodes per year and their incidence is presented in Table  I . More than half (62%, n = 80) of the 129 episodes occurred in the ICU. Figure 1 shows the distribution of candidaemia in the different departments.
Patient demographics and clinical characteristics
The mean age of patients was 62.8 years overall, and 60.1% were male. Eighty-three (64.8%) patients were admitted with a surgical diagnosis, and 55.5% of the patients had major abdominal surgery before the detection of candidaemia. Among underlying diseases of Candida BSI, solid malignancy was the most prevalent (30.5%), followed by diabetes mellitus (24.2%), and immunosuppression (19.5%).
The mean time to blood culture positivity was 1.41 days overall (range 0.37-5.64 days), with blood cultures containing C. glabrata requiring longer incubation time to positivity (2.67 days on average, range 0.43-5.64) than the other species.
Previous colonization in at least one site by the same Candida sp. that was isolated from the bloodstream was detected in 99 episodes (77.3%). The sites of colonization were the respiratory tract (46.9%), the urinary tract (22.6%), an intravascular device (35.9%), and wounds (23.4%). The source of Candida BSI was identifi ed in 74 cases: four bloodstream isolates originated from the urinary tract, 17 from an abdominal abscess or peritoneal infection, three from deep skin infections, three from the mediastinum, and one case of endocarditis was identifi ed. Forty-six (35.9%) episodes were associated with a central venous line. Demographic data and clinical characteristics are summarized in Table II. Overall 30-day mortality was 50.8%, whereas 30-day mortality the highest (90.9%) with C. tropicalis BSI and the lowest with C. krusei (25%) and C. parapsilosis (27.3%).
Univariate analysis was performed to assess if any risk factors of candidaemia could be associated with a higher mortality rate. No such connection was detected; p values are presented in Table III .
Isolate characteristics
A total of 136 isolates were collected. The most frequently isolated species was C. albicans (63%), followed by C. glabrata (13%), C. parapsilosis (10.2%), C. tropicalis (9.3%), and C. krusei (3.7%). C. kefyr caused one episode Seven cases (6.9%) of BSI with multiple Candida spp. were recorded. C. albicans and C. glabrata were isolated in four cases, C. albicans and C. parapsilosis in one case, C. albicans and C. tropicalis in one case, and C. parapsilosis and C. glabrata in one case. There was no signifi cant change in the percentage of C. albicans per year (63% of all isolates) during the study period, but the rate of species with decreased susceptibility or resistance to fl uconazole increased from 10.5% in 2010 to 39.3% in 2014 (p < 0.005). Figure 2 shows species distribution between 2010 and 2014.
All isolates were wild-type organisms and no acquired resistance was detected based on EUCAST breakpoints and available epidemiological cut-off values. The antifungal MIC range, MIC 50 and MIC 90 values are presented in Table IV .
Discussion
The incidence of Candida BSI at our institute increased between 2010 and 2013 (R 2 = 0.9) from 1.7 to 3.5 episodes / 10 000 admissions, in agreement with worldwide trends, but dropped back to 2.66 episodes / 10 000 admissions in 2014. The incidence rate is similar to previous Hungarian data and results from other European centers [20, 21, 22] . The decrease in incidence during the last study year may be explained by the administration of prophylactic antifungal therapy by clinicians after the problem of increasing rates of Candida BSI was detected.
C. albicans was the most frequently isolated species (63%), and the percentage of C. albicans isolates per year did not change signifi cantly during the study period. Several studies have detected a shift towards non-albicans Candida spp., especially C. glabrata, causing BSI [23] . This trend was observed at our institute as well, with the number of non-albicans isolates increasing steadily from 2010 to 2014. The number of C. glabrata isolates increased from 2 isolates in 2010 to 9 isolates in 2014.
Candidaemia was especially prevalent in patients in the ICU after abdominal surgery: the majority of our cases (60.9%) occurred in the ICU, and over half (55.5%) following major abdominal surgery. These fi ndings mirror the results of Kuhns et al., who in a survey of 47 707 cases determined that 20.7% of BSI in the ICU following abdominal surgery were caused by Candida spp. [24] .
Solid malignancy was a major risk factor of candidaemia, present in 30.5% of the patients. Surveillance cultures are recommended in patients at risk to detect colonization by Candida spp. [25] , which precluded Candida BSI at our institute in 77.3% of cases. Eight cases (6.25%) of BSI caused by more than one Candida spp. were detected. Polyfungal candidaemia is uncommon and has been associated with severe underlying disease, use of intravascular catheter, treatment at ICU, prior antibiotic exposure and heavy colonization with Candida spp. [26] . Signifi cant statistical results could not be achieved due to the small sample size, but patients with multiple Candida isolates suffered from solid malignant disease (37.5%), and received TPN more frequently (62.5%) compared with overall rates.
Acquired resistance to at least one group of antifungals has been detected in case of several Candida spp. Reports of multi-resistant C. glabrata isolates resistant to azoles, echinocandins and amphotericin B are especially alarming [27, 28] . All the isolates in our study were wild-type organisms, indicating that acquired antifungal resistance of Candida spp. is not an issue in Hungary yet. The emergence of resistant isolates has been linked with prior antifungal treatment. Echinocandin treatment has only recently been implemented in Hungarian routine clinical care, explaining why resistant isolates have not been detected yet. What is especially daunting is the fact that isolates resistant to echinocandins are frequently resistant to amphotericin B as well, posing a serious therapeutic challenge to clinicians.
The overall 30-day mortality rate at our institute was higher (50.8%) than fi gures reported in other European and US centers (22-37%) [29, 30] . Mortality rate by species was the highest for C. tropicalis (90.9%) and C. albicans (50.7%); these two species are the most virulent compared with other species and have been associated with higher mortality rates in BSI [31] , though the mortality rate for C. tropicalis may be falsely high due to the small sample size.
No risk factors of Candida BSI were found to be signifi cantly associated with patient mortality.
This study describes the local epidemiology and antifungal susceptibility at a university hospital. The incidence of Candida BSI increased during the study period, and fl uconazole non-susceptible species became more prevalent. Rare Candida spp., such as C. fabianii and C. inconspicua were identifi ed as cause of BSI. No isolates with acquired antifungal resistance were detected. Surveillance of Candida BSI should be continued in the future to assess changes in epidemiology and to monitor antifungal resistance.
